Serina Therapeutics, Inc. (SER)

In October 2025, Serina Therapeutics received the first $5 million funding tranche to support the registrational trial of SER-252. On November 3, 2025, the stock experienced a pre-market decline. On November 13, 2025, following its Q3 earnings report, Serina Therapeutics' shares declined by 2.5%. On December 11, 2025, the company received a deficiency notification from the NYSE regarding its shareholders' equity. In January 2026, the FDA cleared the IND application for SER-252. In February 2026, Serina Therapeutics announced the enrollment and dosing of the first patient in its Phase 1b registrational trial for SER-252 in Australia. In March 2026, the company secured up to $30 million in private placement financing to advance the registrational trial of SER-252, leading to a surge in the stock price. On March 23, 2026, Randall Moreadith, the Chief Scientific Officer, sold 6,500 shares of common stock. On March 25, 2026, Serina Therapeutics reported its full-year 2025 financial results, indicating a net loss of $19.4 million.

There is no readily available information indicating specific demand seasonality for Serina Therapeutics' products and services. The demand for its products is primarily driven by the progress of its clinical trials, regulatory approvals, and potential future commercialization, rather than typical seasonal consumer patterns.

Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates to treat neurological diseases and pain, utilizing its proprietary POZ Platform delivery technology. The platform aims to improve the efficacy and safety of therapeutics, including SER 252 for Parkinson's disease, SER 214 for early Parkinson's and Restless Leg Syndrome, POZ-lipids as a non-immunogenic alternative to PEG-lipids, POZ technology for RNA vaccines, and other CNS indications like epilepsy and pain. The company also licenses its POZ polymer for use in lipid nanoparticle drug delivery, including a non-exclusive agreement with Pfizer, Inc.

Serina Therapeutics is headquartered in Huntsville, Alabama, United States. The company has initiated a Phase 1b registrational trial for SER-252 in advanced Parkinson's disease, with study sites located in both Australia and the United States.

Over the past year, Serina Therapeutics' brand reputation on Stocktwits has been neutral, with message volume increasing from normal to high levels. Events impacting the company's reputation include the FDA placing a clinical hold on its application to initiate clinical trials for SER-252 (though later cleared), receiving a NYSE deficiency notification, the FDA clearance of the IND for SER-252, the initiation of the Phase 1b trial, and securing significant private placement financing.

Serina Therapeutics' ownership is a mix of institutional, retail, and individual investors. Approximately 3.67% of the company's stock is held by institutional investors, 1.51% by insiders, and 94.82% by public companies and individual investors. Major institutional owners include Vanguard Group Inc, Warren Averett Asset Management, LLC, Broadwood Capital Inc, Geode Capital Management, Llc, Linscomb & Williams, Inc., Keel Point, LLC, BlackRock, Inc., Northern Trust Corp, State Street Corp, HighTower Advisors, LLC, Juvenescence Ltd., and Puffinus, Inc.